Update on Johnson & Johnson vaccine

The CDC and FDA recommend vaccinators pause administering the Johnson & Johnson COVID-19 vaccine. In six cases out of 6.8 million Johnson & Johnson doses given in the U.S., patients reported a rare and severe type of blood clot. In all six cases, women between the ages of 18 and 48 reported symptoms six to 13 days after vaccination.

What you should know

• This pause is appropriate and proof the national monitoring of COVID-19 vaccine is working well.
• Instances of blood clots are rare, but we need to make sure the vaccine is safe. Additional study will provide these answers.
• Gundersen staff have provided 1,227 Johnson & Johnson doses to patients across our system, since April 1.
• No severe reactions have been reported among those who have received Johnson & Johnson vaccine from Gundersen.
• We will store doses of Johnson & Johnson vaccine still on hand at our locations and wait for guidance from the CDC and FDA.
• If you received the Johnson & Johnson vaccine, seek medical attention if your leg or arm begins to cramp, swell or becomes warm to the touch.